Twist Bioscience Stock Price, News & Analysis

Twist Bioscience Corporation (NASDAQ: TWST) has announced a collaboration with Artisan Development Labs Inc. to discover novel antibodies for five undisclosed targets. Twist will utilize its proprietary Library of Libraries, while Artisan will employ its Immune Cell Engineering Foundry to develop custom cell therapeutics. The partnership includes upfront fees, success-based milestones, and royalties on product sales. This collaboration aims to enhance antibody discovery and advance next-generation cell therapies, combining Twist's DNA synthesis platform with Artisan's engineering capabilities.

Twist Bioscience Corporation (NASDAQ: TWST) will announce its financial results for the first quarter of fiscal 2022, ending December 31, 2021, before the market opens on February 4, 2022. A conference call will be held at 8:00 a.m. ET to discuss these results and provide business updates. Investors can access the press release on the company's website prior to the call. Twist Bioscience, known for its silicon-based DNA synthesis platform, continues to innovate in synthetic biology, with applications across multiple industries including healthcare and agriculture.

Twist Bioscience Corporation has announced a breakthrough in DNA synthesis with its new enzymatic synthesis process, offering low-cost, scarless, and scalable technology. The innovation reduces the nucleotide triphosphate (NTP) requirement, significantly cutting costs and enhancing sustainability. Additionally, Twist is partnering with PacBio and Singular Genomics to streamline next-generation sequencing workflows. CEO Emily M. Leproust will present these advancements at the 40th Annual J.P. Morgan Healthcare Conference, aimed at expanding applications in various markets.

Twist Bioscience Corporation (NASDAQ: TWST) has announced the launch of the Twist Alliance Canine Exome Panel, designed for canine genomic research in partnership with the Broad Institute. This panel facilitates next-generation sequencing (NGS) and covers all coding exons of canine genes, including regions relevant to human diseases like cancer. Starting February 2022, the panel aims to enhance comparative studies between human and canine genomics, potentially benefiting both species' health.

Twist Bioscience Corporation (TWST) and Revelar Biotherapeutics announced that their bispecific antibody, RBT-0813, effectively neutralizes the Delta and Omicron variants of SARS-CoV-2 in live virus studies. This innovative antibody, discovered by Twist Biopharma, is progressing in preclinical development with the aim to submit an Investigational New Drug application (IND) in the first half of 2022. The antibody's efficacy was independently confirmed by a team at Yale School of Medicine.

Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust, Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10 at 4:30 p.m. ET. The presentation will be available via a live webcast, accessible through the company’s investor relations page. Following the event, a replay will be archived for 30 days.

Twist is a leader in synthetic biology, utilizing a unique silicon-based platform for DNA synthesis, producing various synthetic DNA products for multiple industries, including healthcare, agriculture, and drug development.

Twist Bioscience Corporation has introduced the Twist 96-Plex Library Prep Kit, designed for next-generation sequencing (NGS), enhancing lab workflows and reducing costs. This innovative kit allows multiplexing of up to 960 samples with reduced hands-on time and reagent usage. The kit has already demonstrated significant results, including identifying genetic associations to canine lung disease, previously missed by microarray technology. Twist aims to optimize genetic research, facilitating advanced studies in genomics and synthetic biology at a lower cost.

Twist Bioscience (TWST) has announced a strategic collaboration with Sosei Heptares to develop therapeutic antibodies targeting G protein-coupled receptors (GPCRs). This partnership combines Twist's synthetic antibody libraries and bioinformatics with Sosei Heptares' StaR® platform. Sosei Heptares will hold exclusive rights to develop and commercialize identified antibody leads. Twist will receive upfront payments, ongoing R&D costs, and milestone payments, though specific financial terms are not disclosed. This alliance aims to expand opportunities in GPCR-targeted antibody therapeutics, addressing a significant area in drug development.

Twist Bioscience Corporation (NASDAQ: TWST) announced the availability of synthetic RNA positive controls for the SARS-CoV-2 Omicron variants, aiding in pandemic response. As of December 6, 2021, Omicron has been confirmed in over 50 countries, prompting the need for effective diagnostics and therapeutic development. CEO Emily M. Leproust emphasized the company's commitment to developing tools to combat COVID-19 variants. Twist also offers a suite of next-generation sequencing tools and is working on controls for the BA.2 variant. The company adheres to strict biosecurity protocols for customer purchases.